Memantine Orion

Memantine, the active ingredient in Memantine Orion, is an NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, helping to reduce excitotoxic neuronal damage and support cognitive function.

GNH USA supplies Memantine Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other global markets.

Memantine is an NMDA receptor antagonist used in the management of Alzheimer’s disease.

- Moderate to severe Alzheimer’s disease: improves cognition and functional abilities in adults with established disease.

Memantine may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Hypertension - Insomnia

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmias - Severe hepatic dysfunction - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior - Severe skin reactions such as bullous pemphigoid

When prescribing Memantine Orion, clinicians should consider several safety aspects.

- Renal impairment: assess renal function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes regularly. - History of seizures: use with caution and monitor neurologic status. - Concomitant NMDA antagonists: avoid additive central nervous system effects. - Pregnancy: safety not established; weigh potential benefits against risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity. - Other NMDA antagonists (e.g., ketamine): additive CNS depression. - Strong CYP450 inducers (e.g., carbamazepine, phenytoin): may lower memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors (e.g., donepezil): may enhance therapeutic effect. - Diuretics: potential impact on blood pressure. - Alcohol: may exacerbate dizziness and sedation. - Antihypertensive agents: monitor for additive blood pressure lowering.